Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1952 1
1967 1
1968 2
1969 1
1970 3
1971 2
1972 2
1973 3
1974 2
1975 8
1976 6
1977 5
1978 10
1979 7
1980 8
1981 7
1982 6
1983 7
1984 7
1985 5
1986 10
1987 13
1988 13
1989 18
1990 12
1991 14
1992 11
1993 5
1994 17
1995 24
1996 21
1997 17
1998 12
1999 15
2000 16
2001 8
2002 13
2003 8
2004 11
2005 23
2006 23
2007 23
2008 14
2009 19
2010 9
2011 11
2012 11
2013 17
2014 16
2015 17
2016 21
2017 27
2018 19
2019 23
2020 23
2021 28
2022 43
2023 31
2024 13

Text availability

Article attribute

Article type

Publication date

Search Results

703 results

Results by year

Filters applied: . Clear all
Page 1
Lomustine and Bevacizumab in Progressive Glioblastoma.
Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le Rhun E, Dubois F, Weller M, von Deimling A, Golfinopoulos V, Bromberg JC, Platten M, Klein M, van den Bent MJ. Wick W, et al. Among authors: clement pm. N Engl J Med. 2017 Nov 16;377(20):1954-1963. doi: 10.1056/NEJMoa1707358. N Engl J Med. 2017. PMID: 29141164 Free article. Clinical Trial.
Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study.
van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG. van den Bent MJ, et al. Among authors: clement pm. Lancet Oncol. 2021 Jun;22(6):813-823. doi: 10.1016/S1470-2045(21)00090-5. Epub 2021 May 14. Lancet Oncol. 2021. PMID: 34000245 Free PMC article. Clinical Trial.
Sepsis-associated acute kidney injury in the intensive care unit: incidence, patient characteristics, timing, trajectory, treatment, and associated outcomes. A multicenter, observational study.
White KC, Serpa-Neto A, Hurford R, Clement P, Laupland KB, See E, McCullough J, White H, Shekar K, Tabah A, Ramanan M, Garrett P, Attokaran AG, Luke S, Senthuran S, McIlroy P, Bellomo R; Queensland Critical Care Research Network (QCCRN). White KC, et al. Among authors: clement p. Intensive Care Med. 2023 Sep;49(9):1079-1089. doi: 10.1007/s00134-023-07138-0. Epub 2023 Jul 11. Intensive Care Med. 2023. PMID: 37432520 Free PMC article.
CD4+ T cell activation distinguishes response to anti-PD-L1+anti-CTLA4 therapy from anti-PD-L1 monotherapy.
Franken A, Bila M, Mechels A, Kint S, Van Dessel J, Pomella V, Vanuytven S, Philips G, Bricard O, Xiong J, Boeckx B, Hatse S, Van Brussel T, Schepers R, Van Aerde C, Geurs S, Vandecaveye V, Hauben E, Vander Poorten V, Verbandt S, Vandereyken K, Qian J, Tejpar S, Voet T, Clement PM, Lambrechts D. Franken A, et al. Among authors: clement pm. Immunity. 2024 Mar 12;57(3):541-558.e7. doi: 10.1016/j.immuni.2024.02.007. Epub 2024 Mar 4. Immunity. 2024. PMID: 38442708
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH-wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial.
Tesileanu CMS, Sanson M, Wick W, Brandes AA, Clement PM, Erridge SC, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Rudà R, Weller M, McBain C, van Linde ME, Aldape K, Jenkins RB, Kros JM, Wesseling P, von Deimling A, Hoogstrate Y, de Heer I, Atmodimedjo PN, Dubbink HJ, Brouwer RWW, van IJcken WFJ, Cheung KJ, Golfinopoulos V, Baumert BG, Gorlia T, French PJ, van den Bent MJ. Tesileanu CMS, et al. Among authors: clement pm. Clin Cancer Res. 2022 Jun 13;28(12):2527-2535. doi: 10.1158/1078-0432.CCR-21-4283. Clin Cancer Res. 2022. PMID: 35275197 Free PMC article. Clinical Trial.
Trial watch: chemotherapy-induced immunogenic cell death in oncology.
Sprooten J, Laureano RS, Vanmeerbeek I, Govaerts J, Naulaerts S, Borras DM, Kinget L, Fucíková J, Špíšek R, Jelínková LP, Kepp O, Kroemer G, Krysko DV, Coosemans A, Vaes RDW, De Ruysscher D, De Vleeschouwer S, Wauters E, Smits E, Tejpar S, Beuselinck B, Hatse S, Wildiers H, Clement PM, Vandenabeele P, Zitvogel L, Garg AD. Sprooten J, et al. Among authors: clement pm. Oncoimmunology. 2023 Jun 3;12(1):2219591. doi: 10.1080/2162402X.2023.2219591. eCollection 2023. Oncoimmunology. 2023. PMID: 37284695 Free PMC article. Review.
Advanced MR Techniques for Preoperative Glioma Characterization: Part 2.
Hangel G, Schmitz-Abecassis B, Sollmann N, Pinto J, Arzanforoosh F, Barkhof F, Booth T, Calvo-Imirizaldu M, Cassia G, Chmelik M, Clement P, Ercan E, Fernández-Seara MA, Furtner J, Fuster-Garcia E, Grech-Sollars M, Guven NT, Hatay GH, Karami G, Keil VC, Kim M, Koekkoek JAF, Kukran S, Mancini L, Nechifor RE, Özcan A, Ozturk-Isik E, Piskin S, Schmainda KM, Svensson SF, Tseng CH, Unnikrishnan S, Vos F, Warnert E, Zhao MY, Jancalek R, Nunes T, Hirschler L, Smits M, Petr J, Emblem KE. Hangel G, et al. Among authors: clement p. J Magn Reson Imaging. 2023 Jun;57(6):1676-1695. doi: 10.1002/jmri.28663. Epub 2023 Mar 13. J Magn Reson Imaging. 2023. PMID: 36912262 Free PMC article. Review.
Advanced MR Techniques for Preoperative Glioma Characterization: Part 1.
Hirschler L, Sollmann N, Schmitz-Abecassis B, Pinto J, Arzanforoosh F, Barkhof F, Booth T, Calvo-Imirizaldu M, Cassia G, Chmelik M, Clement P, Ercan E, Fernández-Seara MA, Furtner J, Fuster-Garcia E, Grech-Sollars M, Guven NT, Hatay GH, Karami G, Keil VC, Kim M, Koekkoek JAF, Kukran S, Mancini L, Nechifor RE, Özcan A, Ozturk-Isik E, Piskin S, Schmainda K, Svensson SF, Tseng CH, Unnikrishnan S, Vos F, Warnert E, Zhao MY, Jancalek R, Nunes T, Emblem KE, Smits M, Petr J, Hangel G. Hirschler L, et al. Among authors: clement p. J Magn Reson Imaging. 2023 Jun;57(6):1655-1675. doi: 10.1002/jmri.28662. Epub 2023 Mar 3. J Magn Reson Imaging. 2023. PMID: 36866773 Free PMC article. Review.
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study.
Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, Clement PM, Mesia R, Kutukova S, Zholudeva L, Daste A, Caballero-Daroqui J, Keam B, Vynnychenko I, Lafond C, Shetty J, Mann H, Fan J, Wildsmith S, Morsli N, Fayette J, Licitra L. Ferris RL, et al. Among authors: clement pm. Ann Oncol. 2020 Jul;31(7):942-950. doi: 10.1016/j.annonc.2020.04.001. Epub 2020 Apr 12. Ann Oncol. 2020. PMID: 32294530 Free article. Clinical Trial.
703 results